GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Asset Turnover

Interpace Biosciences (Interpace Biosciences) Asset Turnover : 0.75 (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Interpace Biosciences's Revenue for the three months ended in Dec. 2023 was $10.28 Mil. Interpace Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $13.64 Mil. Therefore, Interpace Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 was 0.75.

Asset Turnover is linked to ROE % through Du Pont Formula. Interpace Biosciences's annualized ROE % for the quarter that ended in Dec. 2023 was -5.73%. It is also linked to ROA % through Du Pont Formula. Interpace Biosciences's annualized ROA % for the quarter that ended in Dec. 2023 was 26.11%.


Interpace Biosciences Asset Turnover Historical Data

The historical data trend for Interpace Biosciences's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Asset Turnover Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.59 0.67 0.79 1.17 2.77

Interpace Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.53 0.62 0.69 - 0.75

Competitive Comparison of Interpace Biosciences's Asset Turnover

For the Diagnostics & Research subindustry, Interpace Biosciences's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's Asset Turnover Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Asset Turnover falls into.



Interpace Biosciences Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Interpace Biosciences's Asset Turnover for the fiscal year that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2023 )/( (Total Assets (A: Dec. 2022 )+Total Assets (A: Dec. 2023 ))/ count )
=40.214/( (15.979+13.021)/ 2 )
=40.214/14.5
=2.77

Interpace Biosciences's Asset Turnover for the quarter that ended in Dec. 2023 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=10.283/( (14.25+13.021)/ 2 )
=10.283/13.6355
=0.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Interpace Biosciences  (OTCPK:IDXG) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Interpace Biosciences's annulized ROE % for the quarter that ended in Dec. 2023 is

ROE %**(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=3.56/-62.176
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(3.56 / 41.132)*(41.132 / 13.6355)*(13.6355/ -62.176)
=Net Margin %*Asset Turnover*Equity Multiplier
=8.66 %*3.0165*-0.2193
=ROA %*Equity Multiplier
=26.11 %*-0.2193
=-5.73 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Interpace Biosciences's annulized ROA % for the quarter that ended in Dec. 2023 is

ROA %(Q: Dec. 2023 )
=Net Income/Total Assets
=3.56/13.6355
=(Net Income / Revenue)*(Revenue / Total Assets)
=(3.56 / 41.132)*(41.132 / 13.6355)
=Net Margin %*Asset Turnover
=8.66 %*3.0165
=26.11 %

Note: The Net Income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Interpace Biosciences Asset Turnover Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (Interpace Biosciences) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.
Executives
Christopher Mccarthy officer: Principal Financial Officer C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal director 2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell director, officer: President and CEO 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel officer: Chief Financial Officer REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca director C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan director C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p. 10 percent owner 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy director 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership 10 percent owner 55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev director, 10 percent owner C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg officer: Chief Accounting Officer INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard officer: Chief Commerical Officer C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054

Interpace Biosciences (Interpace Biosciences) Headlines

From GuruFocus

Interpace Biosciences Announces Path Forward in Letter to Shareholders

By GlobeNewswire GlobeNewswire 02-17-2021